feladilimab (GSK3359609)

News alerts, weekly reports and conference planners

Company:

GSK

Drug class:

ICOS agonist

Related drugs:

PD-1 expression	Urothelial Cancer	PD-1 expression	Urothelial Cancer	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials pembrolizumab + GSK3359609 Sensitive : C3	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials pembrolizumab + GSK3359609 Sensitive : C3
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials pembrolizumab + GSK3359609 Sensitive : C3	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials pembrolizumab + GSK3359609 Sensitive : C3

Associations
(2)